Myeloma

Top Story

FDA accepts supplemental application for Xgeva to treat patients with multiple myeloma

June 20, 2017

The FDA accepted a supplemental biologics application that seeks to expand the approval of denosumab to include patients with multiple myeloma, according to the drug’s manufacturer.

Denosumab (Xgeva, Amgen) is the first fully human monoclonal antibody that binds to and neutralizes RANK ligand, a protein that is vital for the formation, function and survival of osteoclasts.

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist, also will serve as…
FDA News

FDA expands Darzalex approval for relapsed myeloma

June 16, 2017
The FDA today expanded the approval of daratumumab as part of combination treatment for patients with relapsed or refractory myeloma. The approval allows for use of…

10 highlights from the ASCO Annual Meeting

June 16, 2017
This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.” HemOnc Today
CME

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

This activity is supported by an educational grant from Shire.

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis…
More »
Video

VIDEO: Toxicities related to immune therapies ‘unpredictable’ but ‘manageable’

June 23, 2016
More »
Featured
At Issue: Multiple Myeloma Resource Center

At Issue: Multiple Myeloma Resource Center

CME

Toward Precision Medicine for Advanced Melanoma Management: Making the Most of Targeted Agents

This activity is supported by an educational grant from Novartis.

The identification and utilization of melanoma specific biomarkers continues to be of importance for diagnosis and…
More »
FDA News

FDA accepts supplemental application for Xgeva to treat patients with multiple myeloma

June 20, 2017
The FDA accepted a supplemental biologics application that seeks to expand the approval of denosumab to include patients with multiple myeloma…

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist…

FDA News

FDA expands Darzalex approval for relapsed myeloma

June 16, 2017
The FDA today expanded the approval of daratumumab as part of combination treatment for patients with relapsed or refractory myeloma. The approval…

10 highlights from the ASCO Annual Meeting

June 16, 2017
This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.” …

Oral contraceptive use does not increase long-term cancer risk

June 14, 2017
Women who used oral contraceptives did not demonstrate increased long-term cancer risk, according to results of the Royal College of General…

Meeting NewsVideo

VIDEO: Visiting expert program helps community providers learn about immuno-oncology

June 12, 2017
CHICAGO — Jarushka Naidoo, MBBCh, spoke with HemOnc Today at the ASCO Annual Meeting about the Institute for Clinical Immuno-Oncology. The…

FDA News

FDA rejects Coherus application for proposed biosimilar to Neulasta

June 12, 2017
The FDA denied approval of Coherus BioSciences’ biologics license application for CHS-1701, a proposed biosimilar for pegfilgrastim. Like…

Lineberger Comprehensive Cancer Center director to lead NCI

June 12, 2017
President Donald J. Trump selected Norman E. “Ned” Sharpless, MD, to serve as director of NCI. Sharpless — recognized for his…

Foundation Medicine announces participation in NCI-MATCH trial

June 7, 2017
Foundation Medicine, NCI and ECOG-ACRIN Cancer Research Group entered a collaboration to evaluate the benefit of genomically guided treatments…

Meeting NewsPerspective

CAR T-cell therapy shows promise for patients with myeloma

June 5, 2017
CHICAGO — All patients with myeloma responded to treatment with BCMA–specific chimeric antigen receptor T-cell therapy, according to…

More Headlines »
Advertisement
Advertisement